Absentia Labs is a biotechnology company based in Boston, Massachusetts, that develops AI foundation models for medicine. The firm's core business involves learning from biological, chemical, and clinical data to model drug behavior, predict safety and efficacy, and accelerate decision-making across the drug development pipeline. It was founded by scientists trained at MIT.
The company's technical work spans several domains, including AI foundation models, in-silico modeling, computational biology, and the prediction of drug-induced liver injury (DILI). Its focus areas sit at the intersection of artificial intelligence, pharmaceuticals, and drug discovery.
Absentia Labs' primary product is the Digital Liver Model, an AI tool designed for predicting DILI. Notably, this model was the first AI drug development tool to be accepted into the U.S. Food and Drug Administration's Drug Development Tool Qualification Program, marking a significant regulatory milestone in the field of AI-driven drug safety assessment.
